Smith & Nephew gets US thumbs-up for OA (osteoarthritis) joint fluid therapy
This article was originally published in Clinica
Executive Summary
Smith & Nephew's Orthopaedics division has planned an April launch in the US for what it claims is already the world's most commonly used viscosupplement for the knee. The company told Clinica of its decision after gaining FDA approval for the product, Surpartz, a joint fluid therapy for treating osteoarthritis (OA).